Ductal carcinoma in situ of the breast: Correlation between histologic classifications and biologic markers

Modern Pathology

Volumn 10, Issue 11, 1997, Pages 1088-1092

  Moreno, Abelardo ^a   Lloveras, Belén ^a   Figueras, Agnès ^a   Escobedo, Agustín ^b   Ramon, Jose Maria ^a   Sierra, Angels ^c   Fabra, Angels ^c  

^a Ciutat Sanitaria de Bellvitge ^*  (Spain)

^b Inst Catala d'Oncologica   (Spain)

^c Institut de Recerca Oncologica   (Spain)

Author keywords

Breast; Ductal carcinoma in situ; Immunohistochemistry

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CARCINOMA IN SITU; DISCRIMINANT ANALYSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NUCLEAR PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030720490     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Holland R, Peterse JL, Milis RR, Eusebi V, Faverly D, van der Vijver MJ, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
2. Stomper PC, Connolly JL. Ductal carcinoma in situ of the breast: correlation between mammographic calcification and tumor subtype. AJR Am J Roentgenol 1992;159:483-5.
3. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Ductal carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982;50:1309-14.
4. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328:1581-6.
5. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995;345:1154-7.
6. Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, Gelmar R, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1992;16:1133-43.
7. Antoni G, Querzoli P, Ferretti S, Magri E, Nenci I. Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. Pathol Res Pract 1996;192:117-23.
8. Bartkova J, Barnes DM, Millis RR, Gullick WJ. Immunohistochemical demonstration of c-erb-B2 protein in mammary ductal carcinoma in situ. Hum Pathol 1990;21:1164-7.
9. Schimmelpenning H, Eriksson ET, Pallis L, Skoog L, Cedermark B, Auer GU. Immunohistochemical c-erb-B2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ. Am J Clin Pathol 1992;97(1 Suppl):S48-S52.
10. Bose S, Lesser ML, Norton L, Rosen PP. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996;120: 81-5.
11. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erb-B2 protein. Cancer 1995;75:2123-31.
12. Lodato RF, Maguire HC, Greene MI, Weiner DB, LiVolsi VA. Immunohistochemical evaluation of c-erb-B2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990;3:449-54.
13. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S. p53 mutations and c-erb-B2 amplification in intraductal and invasive breast carcinoma of high histologic grade. Jpn J Cancer Res 1993; 84:394-401.
14. Poller DN, Bell ECR, Elston CW, Blarney EW, Ellis IO. p53 expression in mammary ductal carcinoma in situ. Relationship to immunohistochemical expression of estrogen receptor and c-erb-B2 protein. Hum Pathol 1993;24:463-8.
15. Poller DN, Silverstein MJ, Galea M, Locker AP, Elston CW, Blarney RW, et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erb-B2 protein expression. Mod Pathol 1994;7:257-62.
16. Perin T, Canzoneri V, Massarut S, Bilodi E, Rossi C, Roncadin M, et al. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Europ J Cancer 1996;32A:1148-55.
17. Killeen JL, Namiki H. DNA analysis of ductal carcinoma in situ of the breast. A comparison with histologic features. Cancer 1991;68:2602-7.
18. Crissman JD, Visscher DW, Kubus J. Image cytophotometric DNA analysis of atypical hyperplasia and intraductal carcinoma of the breast. Arch Pathol Lab Med 1990;114:1249-53.
19. Locker AP, Horrocks C, Gilmour AS, Ellis IO, Dowle CS, Elston CW, et al. Flow cytometric and histological analysis of ductal carcinoma in situ of the breast. Br J Surg 1990;77: 564-7.
20. Lagios MD. Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation Cancer Lett 1995; 90:97-102.